![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/SHUKRAPHAR.png)
Share the post "Shukra Pharmaceuticals ‘s Q3 2024-25 Latest News: Profit Falls by 66.45% Year-on-Year"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company’s sales declined by -43.97 % over the year, substantial increase in net sales/revenue by 90.53 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 79 %. Marginal decrease of -1.08% in other income during this quarter. 🔹 Profit over the Year and quarter: Challenges in sustaining profitability for Shukra Pharmaceuticals Limited. Profit dropped by -66.42 % Year to Year, Shukra Pharmaceuticals Limited’s profitability increased by 487.01 % in this quarter. 🔹 EPS over the Year and quarter: EPS declined by -91.64 % Year to Year. EPS increased by 188 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 18.891 Cr | Rs. 5.555 Cr | Rs. 10.584 Cr | + 90.53 % | -43.97 % |
| Expenses | Rs. 9.34 Cr | Rs. 4.89 Cr | Rs. 6.65 Cr | + 35.99 % | -28.8 % |
| Operating Profit | Rs. 9.55 Cr | Rs. 0.67 Cr | Rs. 3.93 Cr | + 486.57 % | -58.85 % |
| OPM % | 50.55 % | 12.06 % | 37.13 % | + 25.07 % | -13.42 % |
| Other Income | Rs. 0.562 Cr | Rs. 1.017 Cr | Rs. 1.006 Cr | -1.08 % | + 79 % |
| Interest | Rs. 0.07 Cr | Rs. 0.11 Cr | Rs. 0.15 Cr | + 36.36 % | + 114.29 % |
| Depreciation | Rs. 0.51 Cr | Rs. 0.7 Cr | Rs. 0.7 Cr | + 0 % | + 37.25 % |
| Profit before tax | Rs. 9.53 Cr | Rs. 0.88 Cr | Rs. 4.09 Cr | + 364.77 % | -57.08 % |
| Tax % | 1.13 % | 38.4 % | 22.74 % | -15.66 % | + 21.61 % |
| Net Profit | Rs. 9.42 Cr | Rs. 0.54 Cr | Rs. 3.16 Cr | + 485.19 % | -66.45 % |
| EPS in Rs | Rs. 8.61 | Rs. 0.25 | Rs. 0.72 | + 188 % | -91.64 % |
Today, we’re looking at Shukra Pharmaceuticals Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a significant year-over-year sales decline of -43.97 %. However, it did see a marginal increase of 90.53 % from the previous quarter. Expenses ticked up slightly by 35.99 % quarter-on-quarter, aligning with the annual decline of -28.8 %. Operating profit, while down -58.85 % compared to last year, faced a quarter-on-quarter increase of 486.57 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -13.42 %, but an expansion of 25.07 % sequentially. Other income fell by -1.08 % compared to the last quarter, despite an annual growth of 79 %. Interest expenses surged remarkably by 36.36 % from the previous quarter, yet the year-over-year increase remains at a moderate 114.29 %. Depreciation costs climbed by 0 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 37.25 %. Profit before tax declined annually by -57.08 % but saw an increase from the preceding quarter by 364.77 %.
Tax expenses as a percentage of profits increased slightly by 21.61 % compared to last year, with a more notable quarter-on-quarter decrease of -15.66 %. Net profit fell by -66.45 % year-on-year but experienced a 485.19 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -91.64 % but a quarterly rise of 188 %. In summary, Shukra Pharmaceuticals Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 18.891 Cr | Rs. 5.555 Cr | Rs. 10.584 Cr | + 90.53 % | -43.97 % |
| Expenses | Rs. 9.34 Cr | Rs. 4.89 Cr | Rs. 6.65 Cr | + 35.99 % | -28.8 % |
| Operating Profit | Rs. 9.55 Cr | Rs. 0.67 Cr | Rs. 3.93 Cr | + 486.57 % | -58.85 % |
| Net Profit | Rs. 9.42 Cr | Rs. 0.54 Cr | Rs. 3.16 Cr | + 485.19 % | -66.45 % |
| EPS in Rs | Rs. 8.61 | Rs. 0.25 | Rs. 0.72 | + 188 % | -91.64 % |
In reviewing Shukra Pharmaceuticals Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -43.97 % year-on-year, however, there was a minor increase of 90.53 % from the previous quarter. Expenses decreased by -28.8 % compared to the previous year, with a 35.99 % increase quarter-on-quarter. Operating Profit dropped by -58.85 % annually, and saw a 486.57 % increase from the last quarter.
Net Profit showed yearly decrease of -66.45 %, and experienced a 485.19 % increase from the previous quarter. Earnings Per Share (EPS) fell by -91.64 % annually, however rose by 188 % compared to the last quarter. In essence, while Shukra Pharmaceuticals Limited faces strong annual decline indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
